173 related articles for article (PubMed ID: 26992855)
1. [Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases].
Frenel JS; Bally O; Bourbouloux E; Berton-Rigaud D; Campone M; Bachelot T; Heudel PÉ
Bull Cancer; 2016 May; 103(5):507-10. PubMed ID: 26992855
[No Abstract] [Full Text] [Related]
2. Breast cancer brain metastases responding to primary systemic therapy with T-DM1.
Bartsch R; Berghoff AS; Preusser M
J Neurooncol; 2014 Jan; 116(1):205-6. PubMed ID: 24065570
[No Abstract] [Full Text] [Related]
3. Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1.
de Vries CL; Linn SC; Brandsma D
J Neurooncol; 2016 Apr; 127(2):401-3. PubMed ID: 26732082
[No Abstract] [Full Text] [Related]
4. Preliminary results of the concurrent use of radiotherapy for bone metastases and trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.
Géraud A; Xu HP; Beuzeboc P; Kirova YM
Cancer Radiother; 2016 Jun; 20(4):312-3. PubMed ID: 27342941
[No Abstract] [Full Text] [Related]
5. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets.
Cho WC; Roukos DH
Expert Rev Anticancer Ther; 2013 Jan; 13(1):5-8. PubMed ID: 23259420
[No Abstract] [Full Text] [Related]
6. Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases.
Torres S; Maralani P; Verma S
BMJ Case Rep; 2014 Aug; 2014():. PubMed ID: 25123575
[TBL] [Abstract][Full Text] [Related]
7. [Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers].
Guerin M; Sabatier R; Gonçalves A
Bull Cancer; 2015 Apr; 102(4):390-7. PubMed ID: 25790739
[TBL] [Abstract][Full Text] [Related]
8. Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review.
Kalsi R; Feigenberg S; Kwok Y; Tkaczuk K; Mehta M; Chumsri S
Clin Breast Cancer; 2015 Apr; 15(2):e163-6. PubMed ID: 25454740
[No Abstract] [Full Text] [Related]
9. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
Martínez MT; Pérez-Fidalgo JA; Martín-Martorell P; Cejalvo JM; Pons V; Bermejo B; Martín M; Albanell J; Lluch A
Crit Rev Oncol Hematol; 2016 Jan; 97():96-106. PubMed ID: 26318092
[TBL] [Abstract][Full Text] [Related]
10. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
Baron JM; Boster BL; Barnett CM
J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
[TBL] [Abstract][Full Text] [Related]
11. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
[No Abstract] [Full Text] [Related]
12. Activity of T-DM1 in Her2-positive breast cancer brain metastases.
Bartsch R; Berghoff AS; Vogl U; Rudas M; Bergen E; Dubsky P; Dieckmann K; Pinker K; Bago-Horvath Z; Galid A; Oehler L; Zielinski CC; Gnant M; Steger GG; Preusser M
Clin Exp Metastasis; 2015 Oct; 32(7):729-37. PubMed ID: 26303828
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study.
Yardley DA; Krop IE; LoRusso PM; Mayer M; Barnett B; Yoo B; Perez EA
Cancer J; 2015; 21(5):357-64. PubMed ID: 26389758
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
15. Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience.
Okines A; Irfan T; Khabra K; Smith I; O'Brien M; Parton M; Noble J; Stanway S; Somaiah N; Ring A; Johnston S; Turner N
Breast J; 2018 May; 24(3):253-259. PubMed ID: 28833867
[TBL] [Abstract][Full Text] [Related]
16. Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1).
Chung YC; Kuo JF; Wei WC; Chang KJ; Chao WT
PLoS One; 2015; 10(7):e0133072. PubMed ID: 26172389
[TBL] [Abstract][Full Text] [Related]
17. HER2-positive metastatic breast cancer: a changing scenario.
Mustacchi G; Biganzoli L; Pronzato P; Montemurro F; Dambrosio M; Minelli M; Molteni L; Scaltriti L
Crit Rev Oncol Hematol; 2015 Jul; 95(1):78-87. PubMed ID: 25748080
[TBL] [Abstract][Full Text] [Related]
18. [Systemic treatment of brain metastases from breast cancer].
Taillibert S; Conforti R; Bonneterre J; Bachelot T; Le Rhun E; Bernard-Marty C
Cancer Radiother; 2015 Feb; 19(1):36-42. PubMed ID: 25662600
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
Krop I; Winer EP
Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
[TBL] [Abstract][Full Text] [Related]
20. Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab.
Colozza M; Minenza E; Gori S; Fenocchio D; Paolucci C; Aristei C; Floridi P
Cancer Chemother Pharmacol; 2009 May; 63(6):1157-9. PubMed ID: 18987856
[No Abstract] [Full Text] [Related]
[Next] [New Search]
